Skip to main content
Premium Trial:

Request an Annual Quote

NanoCellect Biomedical Raises $10 Million in Series B Funding

NEW YORK (GenomeWeb) – NanoCellect Biomedical, a developer of microfluidic cell sorting technologies, announced today that it has completed a $10 million Series B financing round, including convertible notes.

The financing included the participation of existing investors FusionX Ventures and Agilent Technologies, in addition to new investors Illumina Ventures, Anzu Partners, Vertical Venture Partners, and 5 Prime Ventures.    

"The proceeds from this financing will enable us to continue to expand our commercial activities and accelerate our efforts in highly promising application areas in cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery," NanoCellect President, CEO, and Cofounder Jose Morachis said in a statement.

NanoCellect also announced that Alexis Ji, a partner at Illumina Ventures, has joined its board of directors.

"The ability to sort distinct populations of cells has wide-ranging applications for the research and biopharmaceutical industries," Ji said in a statement. "NanoCellect's plug-and-play, easy-to-use, and maintenance-free microfluidic solutions are a significant leap in making cell analysis and sorting more accessible and affordable."